Epilepsy - Pipeline Review, H2 2012

Global Markets Direct, August 2012, Pages: 218

Epilepsy – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Epilepsy - Pipeline Review, H2 2012', provides an overview of the Epilepsy therapeutic pipeline. This report provides information on the therapeutic development for Epilepsy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epilepsy. 'Epilepsy - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Epilepsy.
- A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Epilepsy pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Epilepsy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Epilepsy therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Epilepsy Therapeutic Products under Development, Key Players in Epilepsy Therapeutics, Epilepsy Pipeline Overview, Epilepsy Pipeline, Epilepsy Pipeline Assessment

2
List of Tables 6
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Epilepsy Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Epilepsy 11
Epilepsy Therapeutics under Development by Companies 13
Epilepsy Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 20
Comparative Analysis 20
Mid Clinical Stage Products 21
Comparative Analysis 21
Early Clinical Stage Products 22
Comparative Analysis 22
Discovery and Pre-Clinical Stage Products 23
Comparative Analysis 23
Epilepsy Therapeutics – Products under Development by Companies 24
Epilepsy Therapeutics – Products under Investigation by Universities/Institutes 28
Companies Involved in Epilepsy Therapeutics Development 29
Kyowa Hakko Kirin Co., Ltd. 29
NsGene A/S 30
Dainippon Sumitomo Pharma Co., Ltd. 31
Neurocrine Biosciences, Inc. 32
Novartis AG 33
Eisai Co., Ltd. 34
H Lundbeck A/S 35
Meiji Holdings Co., Ltd. 36
Pfizer Inc. 37
UCB Group 38
Vertex Pharmaceuticals Incorporated 39
Aeolus Pharmaceuticals, Inc. 40
GW Pharmaceuticals plc 41
Icagen Inc 42
Anavex Life Sciences Corp. 43
Ligand Pharmaceuticals Incorporated 44
Bionomics Limited 45
Neuro-Hitech, Inc. 46
NeuroSearch A/S 47
Catalyst Pharmaceutical Partners, Inc. 48
NPS Pharmaceuticals, Inc. 49
CombinatoRx, Incorporated 50
Proximagen Neuroscience plc. 51
NeuroVive Pharmaceutical AB 52
Paloma Pharmaceuticals, Inc. 53
Bio-Link 54
D-Pharm Ltd. 55
Upsher-Smith Laboratories, Inc. 56
Snowdon Inc. 57
BioMAS Ltd. 58
CREABILIS Therapeutics S.r.l. 59
Ache Laboratorios Farmaceuticos S/A 60
MedGenesis Therapeutix Inc. 61
Chlorion Pharma, Inc. 62
Supernus Pharmaceuticals, Inc. 63
Celentyx Ltd. 64
Nobelpharma Co., Ltd. 65
Concert Pharmaceuticals, Inc. 66
Biovista Inc. 67
Marinus Pharmaceuticals, Inc. 68
Bial - Portela & Ca, S.A. 69
Sihuan Pharmaceutical Holdings Group Ltd. 70
Neurelis, Inc. 71
Vichem Chemie Research Ltd. 72
Epilepsy – Therapeutics Assessment 73
Assessment by Monotherapy Products 73
Assessment by Combination Products 74
Assessment by Route of Administration 75
Assessment by Molecule Type 78
Drug Profiles 81
ANAVEX-2-73 - Drug Profile 81
Vimpat - Drug Profile 82
Vimpat - Drug Profile 85
Brivaracetam - Drug Profile 88
Fycompa - Drug Profile 90
Fycompa - Drug Profile 92
Carbamazepine - Drug Profile 94
ICA-105665 - Drug Profile 96
AEDs - Drug Profile 98
NPSP-156 - Drug Profile 99
CSC 700 Series - Drug Profile 100
Stedesa - Drug Profile 101
CX1010 - Drug Profile 103
Keppra - Drug Profile 104
Vanquix - Drug Profile 106
Tonabersat - Drug Profile 107
Dynamin Modulators - Drug Profile 108
NHT1107 - Drug Profile 110
Cannabinoids For Epilepsy - Drug Profile 111
Topiramate - Drug Profile 112
ANAVEX-19-144 - Drug Profile 113
VX-765 - Drug Profile 115
GABA-A agonists - Drug Profile 117
CT637 - Drug Profile 118
NSD-721 - Drug Profile 119
CLP-290 - Drug Profile 120
YKP3089 - Drug Profile 121
Naluzotan - Drug Profile 123
CPP-115 - Drug Profile 124
NsG0501 - Drug Profile 126
Levetiracetam - Drug Profile 127
DP-VPA - Drug Profile 128
Topiramate - Drug Profile 130
Bumetanide - Drug Profile 131
Carvedilol-CR - Drug Profile 132
Biperiden - Drug Profile 133
AS101 - Drug Profile 134
BGG-492 - Drug Profile 136
Lorazepam - Drug Profile 138
GDNF - Drug Profile 139
Muscimol - Drug Profile 141
USL255 - Drug Profile 142
Ganaxolone - Drug Profile 143
Eicosapentaenoic Acid + Docosahexaenoic Acid - Drug Profile 145
NPC-06 - Drug Profile 147
SPN-804 - Drug Profile 148
Midazolam - Drug Profile 149
Clonazepam + Levetiracetam - Drug Profile 150
Thalidomide - Drug Profile 151
BVA-601 - Drug Profile 152
Palomid 529 Oral - Drug Profile 153
Program For Neurological Disorders - Drug Profile 154
Keppra - Drug Profile 155
KW-6485 - Drug Profile 156
E2080 - Drug Profile 157
AEOL 11207 - Drug Profile 158
stiripentol - Drug Profile 159
C-10068 - Drug Profile 160
UCB0942 - Drug Profile 162
Z944 - Drug Profile 163
Levetiracetam - Drug Profile 164
VLB-01 - Drug Profile 165
Midazolam - Drug Profile 166
Drug For Epilepsy - Drug Profile 167
NRL-01 - Drug Profile 168
NVP017 - Drug Profile 169
Levetiracetam - Drug Profile 171
Huperzine - Drug Profile 172
DSP-0565 - Drug Profile 173
VID-45110 - Drug Profile 174
Epilepsy Therapeutics – Drug Profile Updates 175
Epilepsy Therapeutics – Discontinued Products 199
Epilepsy Therapeutics - Dormant Products 201
Epilepsy – Product Development Milestones 205
Featured News & Press Releases 205
Appendix 212
Methodology 212
Coverage 212
Secondary Research 212
Primary Research 212
Expert Panel Validation 212
Contact Us 213
Disclaimer 213

List of Tables
Number of Products Under Development for Epilepsy, H2 2012 16
Products under Development for Epilepsy – Comparative Analysis, H2 2012 17
Number of Products under Development by Companies, H2 2012 19
Number of Products under Development by Companies, H2 2012 (Contd..1) 20
Number of Products under Development by Companies, H2 2012 (Contd..2) 21
Number of Products under Development by Companies, H2 2012 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H2 2012 24
Comparative Analysis by Late Stage Development, H2 2012 25
Comparative Analysis by Mid Clinical Stage Development, H2 2012 26
Comparative Analysis by Early Clinical Stage Development, H2 2012 27
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 28
Products under Development by Companies, H2 2012 29
Products under Development by Companies, H2 2012 (Contd..1) 30
Products under Development by Companies, H2 2012 (Contd..2) 31
Products under Development by Companies, H2 2012 (Contd..3) 32
Products under Investigation by Universities/Institutes, H2 2012 33
Kyowa Hakko Kirin Co., Ltd., H2 2012 34
NsGene A/S, H2 2012 35
Dainippon Sumitomo Pharma Co., Ltd., H2 2012 36
Neurocrine Biosciences, Inc., H2 2012 37
Novartis AG, H2 2012 38
Eisai Co., Ltd., H2 2012 39
H Lundbeck A/S, H2 2012 40
Meiji Holdings Co., Ltd., H2 2012 41
Pfizer Inc., H2 2012 42
UCB Group, H2 2012 43
Vertex Pharmaceuticals Incorporated, H2 2012 44
Aeolus Pharmaceuticals, Inc., H2 2012 45
GW Pharmaceuticals plc, H2 2012 46
Icagen Inc, H2 2012 47
Anavex Life Sciences Corp., H2 2012 48
Ligand Pharmaceuticals Incorporated, H2 2012 49
Bionomics Limited, H2 2012 50
Neuro-Hitech, Inc., H2 2012 51
NeuroSearch A/S, H2 2012 52
Catalyst Pharmaceutical Partners, Inc., H2 2012 53
NPS Pharmaceuticals, Inc., H2 2012 54
CombinatoRx, Incorporated, H2 2012 55
Proximagen Neuroscience plc., H2 2012 56
NeuroVive Pharmaceutical AB, H2 2012 57
Paloma Pharmaceuticals, Inc., H2 2012 58
Bio-Link, H2 2012 59
D-Pharm Ltd., H2 2012 60
Upsher-Smith Laboratories, Inc., H2 2012 61
Snowdon Inc., H2 2012 62
BioMAS Ltd., H2 2012 63
CREABILIS Therapeutics S.r.l., H2 2012 64
Ache Laboratorios Farmaceuticos S/A, H2 2012 65
MedGenesis Therapeutix Inc., H2 2012 66
Chlorion Pharma, Inc., H2 2012 67
Supernus Pharmaceuticals, Inc., H2 2012 68
Celentyx Ltd., H2 2012 69
Nobelpharma Co., Ltd., H2 2012 70
Concert Pharmaceuticals, Inc., H2 2012 71
Biovista Inc., H2 2012 72
Marinus Pharmaceuticals, Inc., H2 2012 73
Bial - Portela & Ca, S.A., H2 2012 74
Sihuan Pharmaceutical Holdings Group Ltd., H2 2012 75
Neurelis, Inc., H2 2012 76
Vichem Chemie Research Ltd., H2 2012 77
Assessment by Monotherapy Products, H2 2012 78
Assessment by Combination Products, H2 2012 79
Assessment by Stage and Route of Administration, H2 2012 82
Assessment by Stage and Molecule Type, H2 2012 85
Epilepsy Therapeutics – Drug Profile Updates 180
Epilepsy Therapeutics – Discontinued Products 204
Epilepsy Therapeutics – Discontinued Products (Contd..1) 205
Epilepsy Therapeutics – Dormant Products 206
Epilepsy Therapeutics – Dormant Products (Contd..1) 207
Epilepsy Therapeutics – Dormant Products (Contd..2) 208
Epilepsy Therapeutics – Dormant Products (Contd..3) 209

List of Figures
Number of Products under Development for Epilepsy, H2 2012 16
Products under Development for Epilepsy – Comparative Analysis, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 23
Late Stage Products, H2 2012 25
Mid Clinical Stage Products, H2 2012 26
Early Clinical Stage Products, H2 2012 27
Discovery and Pre-Clinical Stage Products, H2 2012 28
Assessment by Monotherapy Products, H2 2012 78
Assessment by Combination Products, H2 2012 79
Assessment by Route of Administration, H2 2012 80
Assessment by Stage and Route of Administration, H2 2012 81
Assessment by Molecule Type, H2 2012 83
Assessment by Stage and Molecule Type, H2 2012 84

Customers who bought this item also bought

• Stroke – Pipeline Review, H1 2013
• The Neurotechnology Industry 2012 Report
• Drug Addiction – Pipeline Review, H1 2013
• Major Depressive Disorder – Pipeline Review, H1 2013
• Chemotherapy Effects – Pipeline Review, H1 2013
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• Fungal Infections – Pipeline Review, H1 2013
• HIV-1 Infection – Pipeline Review, H1 2013
• Alzheimer's Disease – Pipeline Review, H1 2013
• Bipolar Disorder (Manic Depression) – Pipeline Review, H1 2013